Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

A man's rare tumor caused unusual nerve-related symptoms that improved after surgery.

Antiandrogens are the main treatment for hirsutism, with individualized care and safe, affordable options needed.

Lymphatic vessels are essential for health and can be targeted to treat various diseases.

The document reports findings on genetic research, including ethical concerns about genome editing, improved diagnosis of mitochondrial mutations, solving inherited eye diseases, confirming gene roles in epilepsy, linking a gene to aneurysms, and identifying genes associated with age-related macular degeneration.

The document explains hair and nail biology, common hair loss conditions and treatments, oral and genital skin diseases, and the risks and treatments associated with squamous cell carcinoma.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.

The 11th AICPE Congress in Rimini was a major event in European aesthetic plastic surgery.

Obesity leads to physical, metabolic, reproductive issues, higher healthcare costs, and mental health problems.

Male pattern hair loss caused by follicular miniaturization; early diagnosis and treatment can reduce psychological burden.

New therapies are being developed that target integrin pathways to treat various diseases.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

Certain human skin cells marked by CD44 and ALDH are rich in stem cells capable of long-term skin renewal.

R-spondins and their receptors help increase bone growth and may be used to treat bone loss diseases.

The protein ARA70/ELE1 is involved in male pattern baldness, and lower levels of its short form may lead to hair thinning.

The conclusion is that certain genetic factors and blood types may affect COVID-19 severity, but changes in ACE2 and TMPRSS2 genes are not clearly linked to it.

The document concludes that more research is needed to reduce frequent hospital visits, addiction medicine education improves with specific training, early breast cancer surgery findings are emerging, nipple smears are not very accurate, surgery for older melanoma patients doesn't extend life, a genetic condition in infants can often be treated with one drug, doctors are inconsistent with blood clot medication, a certain gene may protect against cell damage, muscle gene overexpression affects many other genes, and some mitochondrial genes are less active in mice with tumors.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

Men with enlarged prostates often have more severe baldness.

Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.

All treatments helped with prostate symptoms, but the combination of dibenyline and finasteride worked best without extra side effects.

Finasteride may increase erectile dysfunction risk in patients with benign prostatic hyperplasia.

Family doctors can manage older men with urinary symptoms using exams, tests, and medications.

A vaccine may prevent benign prostatic hyperplasia (BPH).

Dutasteride caused more penile tissue changes than finasteride, possibly increasing erectile dysfunction risk.

Monascus helps prevent baldness, prostate issues, and may be a natural alternative to medications.

Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.